News articles about STRATA Skin Sciences (NASDAQ:SSKN) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. STRATA Skin Sciences earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned media coverage about the medical device company an impact score of 45.3803262661537 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
STRATA Skin Sciences traded up $0.02, hitting $2.17, during mid-day trading on Friday, Marketbeat.com reports. 71,670 shares of the company’s stock were exchanged, compared to its average volume of 427,301. The company has a market capitalization of $15.19 million, a PE ratio of 1.10 and a beta of 0.75. STRATA Skin Sciences has a fifty-two week low of $1.06 and a fifty-two week high of $2.81. The company has a current ratio of 1.15, a quick ratio of 0.81 and a debt-to-equity ratio of 0.35.
STRATA Skin Sciences (NASDAQ:SSKN) last issued its quarterly earnings data on Monday, April 2nd. The medical device company reported ($0.10) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.27) by $1.17. The business had revenue of $8.60 million for the quarter, compared to the consensus estimate of $7.35 million. STRATA Skin Sciences had a negative return on equity of 36.19% and a negative net margin of 60.23%. analysts predict that STRATA Skin Sciences will post -0.23 EPS for the current fiscal year.
In other STRATA Skin Sciences news, Director Samuel E. Navarro acquired 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 5th. The shares were acquired at an average price of $2.01 per share, with a total value of $40,200.00. Following the purchase, the director now owns 7,000 shares of the company’s stock, valued at approximately $14,070. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Luann Via acquired 25,000 shares of the company’s stock in a transaction that occurred on Friday, June 8th. The shares were acquired at an average cost of $2.14 per share, for a total transaction of $53,500.00. Following the purchase, the director now directly owns 5,000 shares in the company, valued at approximately $10,700. The disclosure for this purchase can be found here. Insiders have purchased a total of 63,000 shares of company stock worth $128,090 in the last ninety days. 9.95% of the stock is currently owned by company insiders.
About STRATA Skin Sciences
STRATA Skin Sciences, Inc, a medical technology company, engages in developing and commercializing products for the treatment of dermatological disorders. Its products include XTRAC and VTRAC devices used for the treatment of psoriasis, vitiligo, and other skin disorders; and MelaFind system, an instrument for aiding dermatologists in the evaluation of clinically atypical pigmented skin lesions, when a dermatologist chooses to obtain additional information before making a final decision to biopsy in order to rule out melanoma.
Receive News & Ratings for STRATA Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STRATA Skin Sciences and related companies with MarketBeat.com's FREE daily email newsletter.